Abbott's Nutrition Drag and Exact Sciences Writedown Set the Bar for Q2

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Abbott typically reports before the market opens, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Abbott's post-earnings price behavior shows significant volatility, with an average absolute Day 0 move of 4.62% and Day 0 range of 4.73%. The most recent earnings on April 16, 2026, saw the stock decline -6.00% on Day 0 with a 5.00% intraday range, followed by a modest +1.40% recovery on Day +1. The January 2026 report triggered the largest reaction in the dataset, with a -10.04% Day 0 decline.

The historical pattern reveals asymmetric risk, with four of the eight reports showing Day 0 declines (including the three largest moves) and four showing gains. Day +1 follow-through has been more consistently positive, averaging +1.77%, suggesting the market often reassesses initial reactions. The 2.85% average Day +1 range indicates continued volatility into the second session.

Investors should prepare for a potential 4-5% move in either direction on earnings day, with historical precedent for double-digit moves when results or guidance disappoint. The pattern suggests initial reactions can be severe, but follow-through often moderates the Day 0 move.

Part 2.2: Options Market Expected Move

The options market is pricing a 4.25% expected move by July 17 expiration (two days out), implying a range of $85.17 to $92.73. This aligns closely with Abbott's 4.62% average historical Day 0 move, suggesting options traders are pricing in typical earnings volatility rather than expecting an outsized reaction. The 87.02% average implied volatility reflects elevated uncertainty, consistent with the stock's recent pattern of significant post-earnings swings.

Part 3: What Analysts Are Saying

Analyst sentiment on Abbott remains decidedly bullish, with the consensus rating at 4.45 out of 5.0 (between Buy and Strong Buy). The current breakdown shows 20 Strong Buys, 2 Moderate Buys, and 7 Holds, with zero sell ratings across the 29 analysts covering the stock. This represents a slight improvement from one month ago when there were 19 Strong Buys, as one analyst upgraded their stance.

The average price target of $116.81 implies 30.8% upside from the current price of $89.27, with the range spanning from a low of $92.00 (3.1% upside) to a high of $143.00 (60.2% upside). The wide target range reflects differing views on the pace of diabetes care growth and margin expansion, though even the most conservative target sits above current levels.

The "improved" sentiment trend indicates analysts have grown more constructive recently, despite the stock's technical weakness. The disconnect between overwhelmingly bullish Wall Street ratings and deteriorating price action suggests analysts see the current level as an attractive entry point, viewing recent weakness as a buying opportunity rather than a fundamental concern. The concentration of Strong Buy ratings—representing 69% of all recommendations—underscores conviction in Abbott's long-term growth trajectory across its diversified healthcare platform.

Part 4: Technical Picture

Abbott's technical setup heading into earnings is decidedly bearish, with the Barchart Technical Opinion showing a 64% Sell signal, deteriorating from 40% Sell one week ago and 80% Sell one month ago. While the signal has moderated slightly from the extreme reading four weeks back, the recent weakening from 40% to 64% over the past week indicates renewed selling pressure.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains negative as the stock struggles below key resistance levels
• Medium-term (50% Sell): Matching sell signal in the intermediate timeframe suggests the downtrend has become entrenched beyond just short-term weakness
• Long-term (100% Sell): Strong sell signal reflects significant deterioration in the longer-term trend, with the stock well below its 200-day moving average

The trend characteristics show "Good" strength with a "Weakening" direction, indicating the current downtrend is well-established and gaining momentum rather than showing signs of exhaustion.

The stock trades at $89.27, positioned above only the 50-day moving average at $89.16 while sitting below all other key timeframes: the 5-day ($91.73), 10-day ($93.29), 20-day ($92.00), 100-day ($96.61), and critically, the 200-day ($110.17). The 23.4% gap below the 200-day average represents significant technical damage, with the descending shorter-term moving averages creating overhead resistance.

Key resistance now clusters in the $91-93 range where the 5-day, 10-day, and 20-day averages converge, forming a formidable barrier to any post-earnings rally attempt. Support sits immediately below at the 50-day average of $89.16, with a break below that level likely triggering further technical selling. The overall setup is cautionary for earnings: Abbott would need to deliver a significant beat with strong guidance to overcome the bearish technical structure, as even in-line results could struggle to generate sustained upside given the weight of overhead resistance and deteriorating momentum across all timeframes.